 |
|
Heart Outcomes Prevention Evaluation–The Ongoing Outcomes Study, Vitamin E, and Age-Related Macular Degeneration—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
In a previous editorial,1 we reported that currently published data demonstrate no apparent association of the use of vitamin E at 400 IU/d with mortality. The article from the Heart Outcomes Prevention Evaluation–The Ongoing Outcomes (HOPE-TOO) trial2 has raised the possibility that vitamin E supplementation may increase heart failure morbidity. This study was an extension of the original HOPE study that tested the role of vitamin E in the prevention of cancer and cardiovascular disease. The primary outcome measures included incident cancers, cancer deaths, and a composite cardiovascular outcome that included myocardial infarction, stroke, cardiovascular death, unstable angina, revascularization, and total mortality. Both the HOPE and HOPE-TOO studies found neither beneficial nor harmful effects of vitamin E for the main outcome measures. Specifically, there were no harmful effects on overall cardiovascular mortality in the extension of this randomized trial of vitamin E. Each of the components of overall . . . [Full Text of this Article]
AUTHOR INFORMATION
Emily Y. Chew, MD;
Traci E. Clemons, PhD
RELATED LETTER
Heart Outcomes Prevention Evaluation–The Ongoing Outcomes Study, Vitamin E, and Age-Related Macular Degeneration
Jose S. Pulido
Arch Ophthalmol. 2006;124(11):1665.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Vitamin E and the Age-Related Eye Disease Study Supplementation for Age-Related Macular Degeneration
Emily Y. Chew and Traci Clemons
Arch Ophthalmol. 2005;123(3):395-396.
EXTRACT
| FULL TEXT
|
